Years Ended December 31 | 2013 | 2012 | 2011 | ||||||||
Primary Care and Women’s Health | |||||||||||
Cardiovascular | |||||||||||
Zetia | $ | 2,658 | $ | 2,567 | $ | 2,428 | |||||
Vytorin | 1,643 | 1,747 | 1,882 | ||||||||
Diabetes and Obesity | |||||||||||
Januvia | 4,004 | 4,086 | 3,324 | ||||||||
Janumet | 1,829 | 1,659 | 1,363 | ||||||||
Respiratory | |||||||||||
Nasonex | 1,335 | 1,268 | 1,286 | ||||||||
Singulair | 1,196 | 3,853 | 5,479 | ||||||||
Dulera | 324 | 207 | 96 | ||||||||
Asmanex | 184 | 185 | 206 | ||||||||
Women’s Health and Endocrine | |||||||||||
NuvaRing | 686 | 623 | 623 | ||||||||
Fosamax | 560 | 676 | 855 | ||||||||
Follistim AQ | 481 | 468 | 530 | ||||||||
Implanon | 403 | 348 | 294 | ||||||||
Cerazette | 208 | 271 | 268 | ||||||||
Other | |||||||||||
Arcoxia | 484 | 453 | 431 | ||||||||
Avelox | 140 | 201 | 322 | ||||||||
Hospital and Specialty | |||||||||||
Immunology | |||||||||||
Remicade | 2,271 | 2,076 | 2,667 | ||||||||
Simponi | 500 | 331 | 264 | ||||||||
Infectious Disease | |||||||||||
Isentress | 1,643 | 1,515 | 1,359 | ||||||||
Cancidas | 660 | 619 | 640 | ||||||||
PegIntron | 496 | 653 | 657 | ||||||||
Invanz | 488 | 445 | 406 | ||||||||
Victrelis | 428 | 502 | 140 | ||||||||
Noxafil | 309 | 258 | 230 | ||||||||
Oncology | |||||||||||
Temodar | 708 | 917 | 935 | ||||||||
Emend | 507 | 489 | 419 | ||||||||
Other | |||||||||||
Cosopt/Trusopt | 416 | 444 | 477 | ||||||||
Bridion | 288 | 261 | 201 | ||||||||
Integrilin | 186 | 211 | 230 | ||||||||
Diversified Brands | |||||||||||
Cozaar/Hyzaar | 1,006 | 1,284 | 1,663 | ||||||||
Primaxin | 335 | 384 | 515 | ||||||||
Zocor | 301 | 383 | 456 | ||||||||
Propecia | 283 | 424 | 447 | ||||||||
Clarinex | 235 | 393 | 621 | ||||||||
Remeron | 206 | 232 | 241 | ||||||||
Claritin Rx | 204 | 244 | 314 | ||||||||
Proscar | 183 | 217 | 223 | ||||||||
Maxalt | 149 | 638 | 639 | ||||||||
Vaccines (1) | |||||||||||
Gardasil | 1,831 | 1,631 | 1,209 | ||||||||
ProQuad/M-M-R II/Varivax | 1,306 | 1,273 | 1,202 | ||||||||
Zostavax | 758 | 651 | 332 | ||||||||
Pneumovax 23 | 653 | 580 | 498 | ||||||||
RotaTeq | 636 | 601 | 651 | ||||||||
Other pharmaceutical (2) | 4,316 | 4,333 | 4,266 | ||||||||
Total Pharmaceutical segment sales | 37,437 | 40,601 | 41,289 | ||||||||
Other segment sales (3) | 6,325 | 6,412 | 6,428 | ||||||||
Total segment sales | 43,762 | 47,013 | 47,717 | ||||||||
Other (4) | 271 | 254 | 330 | ||||||||
$ | 44,033 | $ | 47,267 | $ | 48,047 | ||||||
(1) | These amounts do not reflect sales of vaccines sold in most major European markets through the Company’s joint venture, Sanofi Pasteur MSD, the results of which are reflected in Equity income from affiliates. These amounts do, however, reflect supply sales to Sanofi Pasteur MSD. |
(2) | Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately. |
(3) | Represents the non-reportable segments of Animal Health, Consumer Care and Alliances. The Alliances segment includes revenue from the Company’s relationship with AZLP. |
(4) | Other revenues are primarily comprised of miscellaneous corporate revenues, third-party manufacturing sales, sales related to divested products or businesses and other supply sales not included in segment results. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales (see Note 3). In addition, other revenues in 2013 reflect $50 million of revenue for the out-license of a pipeline compound. |